Monday 9 November 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
2
Average plausibility
77%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
01HealthAfrica

Egypt train collision kills several and injures more than 100

Reports agree that two trains collided in Giza province and carriages derailed, but official injury counts range from 112 to at least 125.

Two trains collided in Egypt’s al-Ayyat district, south of Cairo, on November 8, derailing several carriages. AP reports seven deaths and at least 125 injuries, citing authorities, while NHK’s November 9 coverage gives seven deaths and 112 injuries. Egypt’s president said he ordered an investigation, according to The Guardian and The New York Times.

What holds up

  • ✓The collision and derailment are well supported across the supplied coverage. BBC’s footage description also identifies derailed carriages, adding visual support beyond official statements.
  • ✓Seven deaths and more than 100 injuries appear consistently in AP, DW, NHK and other reports. These outlets largely cite Egyptian authorities, so their matching figures are not separate checks of hospital or death records.
  • ✓The Guardian and The New York Times both report that the president ordered an investigation. That supports the announcement, not any conclusion about what caused the crash.

What doesn't yet

  • ?The injury total remains unsettled: AP and The Guardian report at least 125, while the newer NHK excerpt gives 112. The excerpts do not explain whether officials revised the count or used different reporting cutoffs.
  • ?Africanews contradicts itself, giving seven deaths in its headline but four in its summary. It also describes the Fayoum train traveling in the opposite direction from the route reported by AP and other outlets.
  • ?DW reports that officials deployed 52 ambulances, but the matching DW mobile page and Tempo wording do not provide separate confirmation. These excerpts are not full-article verification, and they do not establish the crash’s cause.

Ask before you share

  • →Has the Health Ministry issued a time-stamped update reconciling the 112 and 125 injury totals?
  • →What have investigators established about why one train struck the other, beyond the president’s promise of an inquiry?
  • →Has Africanews corrected its conflicting death figures and route description?

Sources & original reporting

  1. [1]Deutsche Welle · Published 8 Nov 2026 · dw.com
  2. [2]Associated Press · Published 8 Nov 2026 · apnews.com
  3. [3]Www3 Nhk · Published 9 Nov 2026 · www3.nhk.or.jp
  4. [4]BBC News · Published 8 Nov 2026 · bbc.co.uk
  5. [5]The New York Times · Published 8 Nov 2026 · nytimes.com
  6. [6]The Guardian · Published 8 Nov 2026 · theguardian.com
  7. [7]En Tempo · Published 9 Nov 2026 · en.tempo.co
  8. [8]Africanews · Published 8 Nov 2026 · africanews.com
  9. [9]Deutsche Welle · Published 8 Nov 2026 · amp.dw.com
02HealthGlobal

Baxdrostat report suggests blood pressure benefits may outlast treatment

Reports describe benefits lasting up to two years after treatment in a small, selected group, not proof that baxdrostat can permanently cure high blood pressure.

The Guardian reports that some patients’ blood pressure stayed lower for up to two years after they stopped taking baxdrostat. The i and Mirror describe a follow-up involving 14 patients who had already responded strongly during an initial trial and then continued treatment. The reports raise the possibility of a lasting effect on a hormonal cause of high blood pressure, but the supplied excerpts do not establish a permanent cure.

What holds up

  • ✓The Guardian, the i and Mirror describe lasting benefits after treatment. The i and Mirror agree that the follow-up involved 14 patients selected after substantial initial improvements, an important limit on how widely the results apply.
  • ✓Separate background evidence supports blood pressure lowering during treatment: a July trial abstract indexed by PubMed reports a 14 mm Hg greater reduction in average 24-hour systolic pressure with baxdrostat than placebo at 12 weeks. That does not establish benefits after stopping.

What doesn't yet

  • ?The i suggests baxdrostat could kill hormone-producing tumor cells and have permanent effects; the Guardian and Mirror also use cure language. The excerpts provide no direct evidence of cell destruction, and follow-up lasting up to two years cannot establish permanence.
  • ?The excerpts do not show how many patients reached two years of follow-up, whether there was a comparison group after stopping, or how other medications changed. Mirror reports that just under a quarter stopped all blood pressure treatment, so stopping baxdrostat should not be confused with stopping every medication.
  • ?Only a few outside newsrooms provide relevant coverage of the lasting-effect finding, and other accounts may be missing. UA News explicitly repeats the Guardian; multiple retellings of the same study are not separate clinical confirmation. These snippets are not full-article or study verification.

Ask before you share

  • →How many of the 14 patients maintained lower blood pressure for the full two years, and what other treatments were they taking?
  • →Did researchers compare these selected strong responders with similar patients who stopped treatment, and did they directly measure changes in hormone-producing cells?
  • →Which patients could benefit, and will a larger study confirm lasting effects and assess safety?

Sources & original reporting

  1. [1]The Guardian · Published 8 Nov 2026 · theguardian.com
  2. [2]Inews · Published 7 Nov 2026 · inews.co.uk
  3. [3]Mirror · Published 8 Nov 2026 · mirror.co.uk
  4. [4]Ua · Published 8 Nov 2026 · ua.news
  5. [5]Pubmed Ncbi Nlm Nih · Published 3 Jul 2026 · pubmed.ncbi.nlm.nih.gov